Xconomy | Boston - Business + Technology in the Exponential Economy

Drugs, Biotech, FDA

Genzyme’s Next-Gen Dialysis Drug Approved

Rebecca Zacks 10/22/07

Genzyme (NASDAQ: GENZ) announced that it has gained FDA approval for Renvela (sevelamer carbonate), a drug that helps keep blood levels of phosphorus from getting too high in patients on dialysis. The new drug is a next-generation version of a similar Genzyme drug approved in 1998.


Add Your Thoughts



You will have 10 minutes to edit your post after you press publish.

Comments may be edited for clarity and length, rejected, or deleted. By clicking "Publish," you are agreeing to these Terms and Conditions.

    

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.

© 2007-2008 Xconomy. All rights reserved. Site designed by Matthew Bouchard, produced by Andrew Koyfman, and powered by WordPress.